论文部分内容阅读
为了观察氨酚羟考酮治疗中晚期癌痛的疗效和安全性,对44例中晚期癌症患者随机分为氨酚羟考酮组(A组22例)给予口服氨酚羟考酮片和盐酸曲马多组(B组22例)给予盐酸曲马多片治疗。观察治疗前后疼痛强度(PI)变化,疼痛缓解度(PAR),镇痛有效率及不良反应。两组服药后数字疼痛评分量表(NRS)评分均明显降低(P<0.05),但组间比较差异无统计学意义,P>0.05;A组的镇痛显效率虽高于B组,但差异无统计学意义,P>0.05;两组药物的不良反应主要表现为头晕、嗜睡、恶心、呕吐,不良反应的总发生率差异无统计学意义,P>0.05。初步研究结果提示,氨酚羟考酮治疗中晚期癌痛效果良好,安全可靠,是中晚期癌痛止痛的有效措施之一。
In order to observe the efficacy and safety of oxycodone in the treatment of advanced cancer, 44 cases of advanced cancer were randomly divided into two groups: group A (22 cases) received oral oxycodone and hydrochloric acid Tramadol group (B group 22 cases) given tramadol hydrochloride tablets treatment. Changes of pain intensity (PI), pain relief (PAR), analgesic efficiency and adverse reactions were observed before and after treatment. The NRS scores of the two groups were significantly decreased (P <0.05), but there was no significant difference between the two groups (P> 0.05). Although the pain relief rate of group A was higher than that of group B, There was no significant difference between the two groups (P> 0.05). The adverse reactions of the two groups were mainly dizziness, drowsiness, nausea, vomiting, and adverse reactions with no significant difference (P> 0.05). Preliminary results suggest that the efficacy of oxycodone in the treatment of advanced cancer pain is good, safe and reliable, is one of the effective measures of pain relief in the mid and late cancer pain.